SENP1 and ovarian carcinoma: To test whether SENP1 contributes to cisplatin-resistance in ovarian cancer cells, we depleted SENP1 by siRNA and found SENP1 depletion significantly increased the cell sensitivity to cisplatin in both SKOV3 CR and IGROV1 CR cells (Fig. 7A and B).